• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 11 is a bar diagram depicting absolute rates of treatment persistence for the drugs for UI. The data came from an evidence-based cost utility analysis. The horizontal axis presents the percentage of subjects who discontinued treatment or switched to another drug. The black bars present rates of treatment discontinuation after drugs. The grey columns present rates of switching one drug treatment to another. The figure shows that treatment discontinuation rates were 74.6% after tolterodine IR, 4mg; 58.33% after tolterodine IR, 2mg, 67% after tolterodine ER, 4mg, 58.4% after solifenacin 10mg, 40% after solifenacin 5mg, 53% after propiverine, and 64% after oxybutynin. The figure demonstrates that more than half the patients stop taking drugs for UI after 1 year of treatment. The lowest rates of treatment discontinuation were after 5 mg of solifenacin.

Figure 11Treatment persistence during 1 year of followup of the drugs for UI548

From: Results

Cover of Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness
Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 36.
Shamliyan T, Wyman J, Kane RL.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.